Navigation Links
Mylan Appoints Heather Bresch as Chief Operating Officer
Date:10/2/2007

Promoted from Head of North America

PITTSBURGH, Oct. 2 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced the appointment of Heather Bresch as Chief Operating Officer. Ms. Bresch served previously as Head of North America and Chief Integration Officer. As Chief Operation Officer, Ms. Bresch will be responsible for Mylan's global commercial and technical operations, strategic planning, business development and international affairs, which includes development of Mylan's antiretroviral (ARV) franchise. She will also continue to oversee the integration of Mylan's recent acquisition of Merck Generics.

Ms. Bresch has spent fifteen years with Mylan in various positions of increasing responsibility throughout the company. Most recently, as Head of North America, she had responsibility for Mylan's operations including Mylan Pharmaceuticals, Mylan Technologies, and UDL Laboratories. Prior to this, she served as Senior Vice President of Strategic Development in the Office of the CEO.

In her role as Chief Integration Officer, in addition to leading the integration team working with Merck Generics, Ms. Bresch has overseen the successful integration of Matrix Laboratories, in which Mylan took a controlling stake earlier this year.

Ms. Bresch has been the only non-CEO to serve as Chairman of the Generic Pharmaceutical Association (GPhA), serving an unprecedented two consecutive terms, and is widely acknowledged in the industry for playing a critical role in the passage of the 2003 Medicare Modernization Act, a Congressional revision to the Hatch-Waxman Act of 1984 that focused on ensuring consumers' access to affordable pharmaceuticals.

Mylan's Vice Chairman and CEO Robert J. Coury commented: "At this stage in Mylan's history, it is imperative that we have a Chief Operating Officer in place that knows our company, is a leader in the industry and has the experience and energy required to execute on the opportunities of the new Mylan. Heather is uniquely qualified for this challenging position, given her in-depth knowledge of Mylan, Matrix and Merck Generics and her strong relationships with management and employees across those organizations as a result of leading the integration efforts. She has played an instrumental role in Mylan's strategic development over the last several years, and will continue be a key driver of the Company's future success."

Ms. Bresch earned an MBA and an undergraduate degree in international studies and political science from West Virginia University.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.

For more information about Mylan, please visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Wins Its Amlodipine Case With Pfizer
2. Mylan Announces Tentative FDA Approval for Its ANDA
3. Mylan Announces Final FDA Approval for Fluoxetine Capsules
4. Heather Mills Gives Cooker Demo on Veg Recipes
5. UNAIDS Chief Appeals for Projects to Battle AIDS/HIV
6. EU medical chief says Europe ready for bird flu
7. NHS acting chief’s intervie
8. Reminiscences of Chief Justice’s Call for Quality Medical Educatio
9. Joining The Military My Best Move - US Army Nursing Chief
10. Making Budhia run 65 km absolutely cruel,says Infosys chief
11. WHO Chiefs Sudden Death - A Major Loss To Global Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... ... September 18, 2017 , ... Cosmetic Town, an online ... According to the senior editor of Cosmetic Tow, “Our forum section is an interactive, ... provide answers to other forum members thinking about having cosmetic surgery. The interaction and ...
(Date:9/18/2017)... ... September 18, 2017 , ... Aegis Therapies, a national leader ... executive team adding a Chief Financial Officer following their announcement on January 1, ... support the strategic growth strategy Aegis has defined for the next several years. ...
(Date:9/18/2017)... ... , ... In the age of digital media, limiting screen time among infants ... and a convenient way to soothe fussy children. , According to a recent study, ... sensory development toys completely. , The study, entitled “Is handheld screen time use associated ...
(Date:9/18/2017)... ... September 18, 2017 , ... While Floridians confront the aftermath ... based company, has launched an aid effort focused on the elderly population that was ... over two days and left thousands homeless and displaced. , “The elderly are often ...
(Date:9/18/2017)... ... September 18, 2017 , ... Dallas and Plano Pet Sitting ... Services . The asset-based purchase combines two of the best reviewed and highly ... Park Cities Pet Sitter, says that it was clear from the outset that acquiring ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... INDIANAPOLIS , Sept. 7, 2017  Eli ... today announced actions to streamline operations to more ... to improve its cost structure. Global workforce reductions, ... program, are expected to impact approximately 3,500 positions. ... the company expects annualized savings of approximately $500 ...
(Date:9/7/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... clinical grade cell and tissue hypothermic storage and ... Rice , President and CEO, will be presenting at two ... & Renshaw 19 th Annual Global Investment Conference on ... Pacific time). The conference is being held at the New ...
(Date:9/6/2017)... 6, 2017 Eli Lilly and Company (NYSE: ... new data for galcanezumab and lasmiditan, two investigational treatments ... Headache Society (IHC) taking place Sept. 7-10 in ... highlight new, long-term data from an open-label study evaluating ... (120 mg and 240 mg) for the prevention of ...
Breaking Medicine Technology: